Literature DB >> 194457

Severe disseminated adenovirus infection successfully treated with a thymic humoral factor, THF.

I Varsano, T M Schonfeld, Y Matoth, B Shohat, T Englander, V Rotter, N Trainin.   

Abstract

Adenovirus and other usually benign viral infections may occasionally be associated with severe fulminant disease, often accompanied by acute acquired cellular immunodeficiency. Thymic humoral factor derived from calf thymuses has been demonstrated to have the capacity to restore the immunocompetence of immature, incompetent T cells. This factor was used in the treatment of a 3 1/2-year-old boy who was critically ill with an adenovirus infection and presented evidence of immunocellular deficiency. Within less than 48 hours after the institution of treatment with thymic humoral factor there was a dramatic, progressive clinical improvement, with restoration of the cellular immunocompetence. It is suggested that thymic humoral factor may be beneficial in the treatment of severe viral infections associated with depressed cellular immunocompetence.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 194457     DOI: 10.1111/j.1651-2227.1977.tb07902.x

Source DB:  PubMed          Journal:  Acta Paediatr Scand        ISSN: 0001-656X


  4 in total

1.  Serological studies of adenoviral hepatitis following pediatric liver transplantation.

Authors:  B Koneru; R Atchison; R Jaffe; A Cassavilla; D H Van Thiel; T E Starzl
Journal:  Transplant Proc       Date:  1990-08       Impact factor: 1.066

2.  Adenoviral infections in pediatric liver transplant recipients.

Authors:  B Koneru; R Jaffe; C O Esquivel; R Kunz; S Todo; S Iwatsuki; T E Starzl
Journal:  JAMA       Date:  1987 Jul 24-31       Impact factor: 56.272

Review 3.  Adenoviruses in the immunocompromised host.

Authors:  J C Hierholzer
Journal:  Clin Microbiol Rev       Date:  1992-07       Impact factor: 26.132

4.  Enrichment of in vitro and in vivo immunologic activity of purified fractions of calf thymic hormone.

Authors:  Y Yakir; A I Kook; N Trainin
Journal:  J Exp Med       Date:  1978-07-01       Impact factor: 14.307

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.